Open an account

Alpha Cognition

ACOG · NASDAQ

$8.61+$0.11 (+1.29%)TodayMarket closed ·
Prev close $8.50

About ACOG

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The firm's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.

Employees
71
Headquarters
Vancouver, British Columbia
Listed
Jun 9, 2021
Sector
Health Care
Industry
Biotechnology
Website
alphacognition.com

ACOG key statistics

Market cap
187.51M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
97.33K
Volume
97.85K
Open price
$8.57
High today
$8.94
Low today
$8.45
52 Week high
$10.14
52 Week low
$4.50

Alpha Cognition (ACOG) at a glance

As of Oct 20, 2026, Alpha Cognition (ACOG) shares are priced at $8.61, giving the company a market cap of 187.51M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $8.45 and $8.94. The current price is 1.9% above the day's low and 3.7% below its high.

Volume so far is 97.85K shares, in line with the average of 97.33K shares a day.

Over the past year Alpha Cognition has ranged from $4.50 to $10.14, and now sits 73% of the way up that range.

Alpha Cognition met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.40 per share against an estimate of -$0.3998.

The average analyst price target is $19.38, 125.0% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $19.38
Low
$12.12
Now
$8.61
High
$28.33

ACOG earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 69.4% on average.

  1. Q3 FY24: reported -$0.01 per share against an estimate of -$1.02
  2. Q4 FY24: reported -$0.51 per share against an estimate of -$0.4896
  3. Q1 FY25: reported -$0.13 per share against an estimate of -$0.5916
  4. Q2 FY25: reported -$0.65 per share against an estimate of -$0.5202
  5. Q3 FY25: reported -$0.08 per share against an estimate of -$0.4386
  6. Q4 FY25: reported -$0.31 per share against an estimate of -$0.2754
  7. Q1 FY26: reported -$0.32 per share against an estimate of -$0.3944
  8. Q2 FY26: reported -$0.40 per share against an estimate of -$0.3998

ACOG news

  • Press releaseBusiness Wire

    Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL®

  • Press releaseBusiness Wire

    Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress

  • Press releaseBusiness Wire

    Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Press releaseBusiness Wire

    Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care

  • Press releaseBusiness Wire

    Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Press releaseBusiness Wire

    Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Alpha Cognition Q2 2026 Earnings Call Transcript

  • Press releaseBusiness Wire

    Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update

Similar companies

Companies in the same industry as Alpha Cognition

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.